Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
Status:
Completed
Trial end date:
2018-02-02
Target enrollment:
Participant gender:
Summary
The objectives of this trial are primarily to evaluate the efficacy and safety of BI
655066/ABBV-066 (risankizumab) as compared to placebo over a 24-week treatment period in
severe asthma patients. The primary endpoint is time to first asthma worsening during the
planned 24 week treatment period for active vs. placebo treated patients on top of standard
of care therapy. Upon demonstration of a meaningful clinical response, another important
objective is the identification of biomarkers that can be used to target patients who will
likely respond to treatment with BI 655066/ABBV-066 (risankizumab).